跳至主要内容
临床试验/NCT01937754
NCT01937754Unknown1 期

Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension

Neogenis Laboratories2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2013年1月1日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
30
试验地点
2
主要终点
Reduction in Systolic and Diastolic Blood Pressure Readings

研究概览

简要总结

Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy adults with clinical prehypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults between the ages of 18 to 80 years
  • Two blood pressure readings of >/=135/80 mmHg at rest, thus representing prehypertension
  • Informed consent

排除标准

  • Existence of any significant internal or cardiovascular disease;
  • Current use of any antihypertensive medication.
  • Inability to give informed consent, or fill out standard questionnaires or inability to follow up clinically.

结局指标

主要结局

Reduction in Systolic and Diastolic Blood Pressure Readings

时间窗: 30 days

Two blood pressure readings at rest will be taken at baseline and again after thirty days during the follow-up appointment.

次要结局

  • Improvement in Functional Capacity(30 days)

研究者

发起方
Neogenis Laboratories
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Ernst Schwarz

Attending Cardiologist, Professor of Medicine

Neogenis Laboratories

研究点 (2)

Loading locations...

相似试验